Famciclovir Tablet (Famciclovir)

Adult dose

1. Treatment of herpes zoster Adults: Administer famciclovir 250 mg orally per dose, 3 times daily for 7 days. It is preferable to start treatment as soon as symptoms appear after infection. 2. Treatment of initial genital herpes infection Adults: Administer this medicine 250 mg orally per dose, 3 times daily for 5 days. It is preferable to start treatment as soon as symptoms appear after infection. 3. Treatment of acute recurrent genital herpes infection Adults: Administer this medicine 125 mg orally per dose, 2 times daily for 5 days. It is preferable to start treatment during the prodromal period or as soon as symptoms appear after infection. 4. Suppression of recurrent genital herpes Adults: Administer this medicine 250 mg orally per dose, 2 times daily. Interrupt treatment periodically every 6～12 months to observe whether the natural course of the disease has changed. 5. Patients with renal impairment: Since creatinine clearance of this medicine is decreased in patients with renal impairment, adjust the dosage with caution. Dosage regimens for these patients are as follows. 1) Treatment of herpes zoster and initial genital herpes infection: Creatinine clearance (mL/min/1.73㎡) Dose 30～59 250 mg per dose, 2 times daily 10～29 250 mg per dose, once daily 2) Treatment of acute recurrent genital herpes infection: Creatinine clearance (mL/min/1.73㎡) Dose 30～59 125 mg per dose, 2 times daily 10～29 125 mg per dose, once daily 3) Suppression of recurrent genital herpes infection: Creatinine clearance (mL/min/1.73㎡) Dose 30～59 250 mg per dose, 2 times daily 10～29 125 mg per dose, 2 times daily 4) If only serum creatinine is known, creatinine clearance can be calculated using the following equations. Men: {weight(kg) × (140-age)}/ {72 × serum creatinine(mg/dL)} Women: 0.85 × the value calculated for men 5) Patients with renal impairment undergoing hemodialysis For patients on hemodialysis, administration every 48 hours is preferable, taking the dialysis interval into account. A 4-hour hemodialysis session reduces the plasma concentration of this medicine by approximately 75%; therefore, administer this medicine immediately after dialysis. The recommended dose is 250mg for patients with herpes zoster and 125mg for patients with genital herpes. 6. Patients with hepatic impairment: No dose adjustment is necessary in patients with chronic compensated liver disease. There is insufficient treatment experience in patients with overt chronic decompensated liver disease; therefore, no clear recommended dose has been established.

This drug should not be used in patients who have had allergic reactions to this drug or its components. Additionally, it contains lactose, so patients with lactose intolerance or specific genetic metabolic disorders should also avoid taking it. Patients with impaired kidney function should use this drug cautiously and may need dosage adjustment. This drug does not cure genital herpes, so it is important to avoid sexual contact when symptoms are present and to maintain safe sexual practices. If dizziness or drowsiness occurs while taking, one should refrain from driving or operating machinery. Patients with slightly impaired liver function do not need special dosage adjustments, but caution is advised for those with severe liver impairment due to a lack of sufficient studies. This drug has a low potential for interactions with other medications, but drug concentration changes or side effects should be monitored when used in combination with certain drugs. If pregnant or breastfeeding, careful consideration is needed regarding the use of this medication, and there are no special recommendations for women of childbearing age. It is generally advised not to use in children under 18 years of age due to a lack of established safety and efficacy. Older adults typically do not need dosage adjustments, but adjustments should be made for those with declining kidney function. In case of overdose, appropriate treatment should be administered, and the drug concentration may be lowered through dialysis. This medication should be stored in a tightly sealed container to prevent exposure to air and moisture and kept in a cool, dry place below 30 degrees Celsius, out of reach of children, and should not be transferred to another container.

• headache
• nausea
• thrombocytopenia
• leukopenia
• neutropenia
• dizziness
• confusion
• drowsiness
• hallucinations
• palpitations

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is also advisable to keep it in a cool, dry place below 30 degrees Celsius.

Appearance

White to yellowish oblong film-coated tablet

Package unit

21 tablets per bottle